Best CROs for Rare Disease & Orphan Drug Clinical Trials

Who this guide is for

This guide is for sponsors, clinical operations leads and outsourcing teams choosing a contract research organisation for a rare disease or orphan drug programme. Whether you are looking for the best CRO for rare disease clinical trials globally or a rare disease CRO UK teams can work with closely, the decision usually turns on one question: can this partner find, enrol and keep patients who are few in number and scattered across countries? The ranked list above is a starting point, not a verdict: it shows vendors from the directory, most of whose profiles list rare disease work, but cannot tell you whether a CRO has run a study in your condition, knows the relevant patient organisations, or has the statistical depth to defend a small-sample design. Vendor scores on Clinical Vendor Compare come only from published platform reviews; a vendor with no reviews shows no score.

What a rare disease CRO does — and when you need one

A rare disease CRO plans and runs clinical studies in conditions where the eligible population is small, often genetically defined and spread thinly across many countries. Beyond monitoring, data management and safety, the role leans on patient-finding through registries and expert centres, travel and family support, input on small-sample protocol design, natural-history and registry studies, and regulatory strategy built around orphan designation and paediatric obligations.

It helps to be clear about the boundaries. A generalist full-service CRO may have a rare disease unit, but its default processes may be built for larger studies. A patient recruitment vendor can help find patients but does not run the trial. A regulatory consultancy can prepare an orphan designation application or a scientific advice briefing, but will not manage sites. Specialist laboratories handle the genetic and biomarker testing many protocols depend on. Most programmes combine several of these, so ask who owns the joins.

Typical triggers include a first interventional study after natural-history work, a programme no single country can enrol, a paediatric population, a planned orphan designation or scientific advice request, and a stalled study that needs rescue.

How to evaluate a rare disease CRO

Patient-finding in small, dispersed populations

Ask how feasibility will be built: from registries, expert centres, genetic testing programmes and advocacy networks, or from generic site databases. A credible answer names the centres that actually see your patients and explains how referrals from non-trial hospitals will reach them.

Patient advocacy partnerships

Patient organisations shape awareness, protocol acceptability and retention. Look for a CRO that involves advocates early, in protocol review and burden assessment, rather than only at recruitment. Ask how they manage independence and transparency so the community continues to trust the partnership.

Natural-history and registry data

Where placebo arms are hard to justify, natural-history data can inform endpoint choice, disease-progression assumptions and external comparisons. Ask whether the CRO can design or run a natural-history study, work with existing registries, and handle the data-quality and consent issues that come with secondary use.

Small-sample and adaptive design capability

Probe the biostatistics team's experience with adaptive, Bayesian, crossover and single-arm designs, and with defending those choices to regulators. Ask who would present the design at a scientific advice meeting.

Paediatric and family-centred delivery

Many rare conditions present in childhood. Check experience with age-appropriate consent and assent, paediatric formulations, sampling limits and the guidance in ICH E11(R1). Ask whether home visits or remote assessments are realistic for families.

Orphan designation and regulatory strategy

Orphan designation in the EU, UK and US follows separate processes with different criteria, timing and incentives. A strong partner coordinates designation, scientific advice and paediatric plan requirements across regions. Ask for named regulatory leads and examples of their advice work.

Site strategy and data quality when every patient counts

Rare disease studies often run many sites that each enrol very few patients. Ask how the CRO keeps low-enrolling sites trained and engaged, and how its risk-based monitoring under ICH E6(R3) protects critical data when a single missing assessment matters.

Rare disease CRO vendors at a glance

The table lists vendors whose profiles include rare disease or orphan drugs among their therapeutic areas, so you can compare type, service model, footprint and phases side by side.

Every field comes from each vendor's CVC profile. The table mixes full-service and specialist CROs, with several Europe-focused profiles alongside global and Asia and global footprints. Some list specific phases; others show phases as mixed, so confirm phase experience directly. In most of these profiles rare disease sits alongside oncology, so ask how much of each team's work is genuinely rare disease. Not every ranked vendor appears here: PSI CRO lists neurology and cell and gene therapy but not rare disease on its profile.

Rare disease CRO profiles

IQVIA

IQVIA is listed as a full-service CRO with a full-service plus technology model, a global footprint and headquarters in the United States. Its profile covers Phase I to Phase IV and generalist, oncology and rare disease work across large multi-region portfolios. It is positioned for global, complex programmes needing broad service integration, with strengths in global delivery, cross-functional service depth and data-enabled planning. Where to probe: the profile notes premium pricing and that it may be less agile for very small studies, so ask how the team would be sized for yours.

Precision for Medicine

Precision for Medicine is listed as a specialist CRO with a global footprint and headquarters in the United States. Its therapeutic areas are oncology, rare disease and complex therapies, with a focus on complex, biomarker-rich global programmes, and its strengths include biomarker-driven development and lab services. Phases are shown as mixed. Where to probe: ask how its lab services would support genetic or biomarker endpoints in your indication, and which phases its rare disease teams have delivered.

Parexel

Parexel is listed as a full-service CRO with a global footprint and headquarters in the United States, covering Phase I to Phase IV. Its areas include oncology, neuroscience, rare disease and generalist work across large and mid-size global programmes. It is positioned for programmes with heavy regulatory complexity and global filings, with strengths in regulatory depth and consultative support. Where to probe: the profile notes pricing pressure for smaller biotech budgets, so ask for a team model that fits an early programme.

Worldwide Clinical Trials

Worldwide Clinical Trials is listed as a full-service CRO with a global footprint and headquarters in the United States, covering Phase I to Phase III. Its areas include neuroscience, oncology and rare disease, for mid-size to large global specialist programmes. It is positioned for biotech or specialist programmes wanting high-touch support, therapeutic alignment and flexible outsourcing structures, with senior expert access among its strengths. Where to probe: public proof points are mostly self-described, so ask for rare disease references and verify site reach in the countries where your patients live.

Tigermed

Tigermed is listed as a full-service CRO with an Asia and global footprint and headquarters in China. Its therapeutic areas are oncology, rare disease and medical devices, and it describes large Asia and global programmes. Strengths include clinical trial management, regulatory affairs and site management. Phases are shown as mixed. Where to probe: ask which rare disease studies it has run and how it would coordinate with European or US sites and regulators.

Smerud Medical Research

Smerud Medical Research is listed as a full-service CRO with a specialist service model, a European footprint and headquarters in Norway. Its therapeutic areas are oncology and rare disease, and it describes focused Europe studies. It is positioned for boutique programmes needing full-service capability and clear sponsor-facing accountability, and its profile cites a credible public delivery story across Europe. Phases are shown as mixed. Where to probe: if your patients live beyond Europe, ask how it would reach them.

Cencora (BioPharma Excellence)

Cencora (BioPharma Excellence) is listed as a specialist CRO with a European footprint and headquarters in Germany, covering Phase I to Phase IV. Its therapeutic areas are oncology and rare disease, and it describes focused Europe studies. It is positioned for trials needing focused expertise or complex operational handling, with strengths in expert focus, flexibility and domain depth. Where to probe: very large global programmes needing maximal scale are flagged as a poorer fit, so test how it would support a pivotal study enrolling across regions.

Niche Science & Technology

Niche Science & Technology is listed as a specialist CRO with a European footprint and headquarters in the UK, covering Phase I to Phase IV. Its listed therapeutic areas are rare disease and orphan drugs only, and its headquarters are in the UK. It describes focused Europe studies and is positioned for trials needing focused expertise or complex operational handling. Where to probe: very large global programmes needing maximal scale are flagged as a poorer fit, so plan how later phases would be resourced.

FGK Clinical Research

FGK Clinical Research is listed as a full-service CRO with a global footprint and headquarters in Germany. Its therapeutic areas are oncology and rare disease, and it describes specialist and mid-size global programmes. Strengths include clinical operations and regulatory affairs. Phases are shown as mixed. Where to probe: ask which countries it can activate directly rather than through partners.

Biomapas

Biomapas is listed as a specialist CRO with a European footprint and headquarters in Lithuania, covering Phase I to Phase IV. Its therapeutic areas are oncology and rare disease, across specialist and mid-size Europe programmes. It is positioned for programmes needing filings, compliance, inspection readiness or quality assurance support, with strengths in regulatory know-how, compliance frameworks and inspection readiness. Where to probe: the profile suggests it works best with a clear scope, milestones and document ownership, so define those in the contract.

Engagement and pricing models

Rare disease work is bought like other clinical services: full-service outsourcing, functional service provision on an FTE basis, unit-based contracts priced per site, patient or deliverable, and hybrids that keep some functions in-house. What changes is where the cost sits.

The main cost drivers are the number of countries and sites relative to patients, long enrolment windows that extend management and monitoring, patient and family travel, genetic screening, paediatric logistics, translations, registry builds, and the interim analyses and data monitoring committee work adaptive designs require. Unit-based pricing per site activated can penalise a sponsor whose sites each enrol very few patients, while time-and-materials pricing can drift over a long recruitment period. Ask for proposals that separate fixed management costs from patient-driven costs, explain change orders if the design adapts, and budget patient support explicitly.

Questions to put in your RFP

• Which rare disease studies has your proposed team delivered, and in which conditions?
• How will you build feasibility for our indication, and which registries, expert centres and advocacy groups will you use?
• How do you involve patient organisations in protocol design and burden assessment?
• Can you design or run a natural-history study, and how would it connect to the interventional programme?
• What small-sample or adaptive designs has your biostatistics team defended with regulators?
• How will you coordinate orphan designation, scientific advice and paediatric plan requirements across the EU, UK and US?
• What is your approach to paediatric assent, caregiver support and home or remote visits?
• How do you keep low-enrolling sites trained, engaged and compliant?
• How are patient travel and family support arranged, paid and reconciled?
• How would pricing and change orders work if enrolment is slower than planned?

Due-diligence red flags

• Feasibility based on generic site databases rather than named expert centres and registries.
• No clear plan for working with patient advocacy groups, or a plan that starts only at recruitment.
• Rare disease credentials that turn out to be large-indication studies relabelled.
• A statistics team that defaults to conventional designs without discussing small-sample alternatives.
• No named regulatory lead for orphan designation or paediatric planning.
• Paediatric experience that does not extend to assent, sampling limits or caregiver burden.
• Site-activation pricing that rewards opening sites rather than enrolling patients.
• Senior specialists shown in the pitch who will not work on the study.

Shortlist on Clinical Vendor Compare

Start in the vendor directory, filter for rare disease experience and open each profile to check footprint and stated fit. Use compare to view your shortlist side by side, then send a structured brief through sponsor RFP so each CRO answers the same questions. If you have worked with any of these vendors on a rare disease study, please write a review. Your experience helps other sponsors serving small patient communities choose well.